治疗阿尔茨海默氏症的药物将于2019年底推出
Treatment for Alzheimer's available by end of 2019
339字
2019-12-04 10:01
114阅读
火星译客

A home-grown drug treating Alzheimer's disease, the first innovative drug in this area in the past 17 years globally, will be available to Chinese patients before the end of this year, the medicine developer officially announced on Sunday after the country's drug authority approved its market launch the day before.

在中国国家药品监督管理总局于周六批准上市后,这家医药开发商周日正式宣布,将在今年年底前向中国患者推出治疗阿尔茨海默症的国产药物,这是17年来全球在这一领域的首个创新药物。

The oral drug, GV-971, is the only one out of more than 320 developed by pharmaceutical companies around the globe that succeeded after clinical trials. The drug has been found to be capable of treating mild-to-moderate Alzheimer's disease and can improve cognition, according to the National Medical Products Administration.

口服药物 GV-971 是全球320多家制药公司开发的药物中唯一一种在临床试验后获得成功的药物。据国家药品监督管理局(National Medical Products Administration)称,该药物能够治疗轻度至中度的阿尔茨海默氏症,改善患者认知功能。

The first production line of the drug, which will meet the needs of 2 million patients, will begin within a week, and patients will be able to buy the drugs through sales channels all over the country from Dec 29. More production lines will be put into operation to gradually satisfy market expectation, drug developers said.

该药品的第一条生产线将在一周内投产,满足200万患者的需求,从12月29日起,患者将能够通过全国各地的销售渠道购买药品。药品开发商表示,后续将有更多的生产线投入使用,以逐步满足市场需求。

5dbe908ea310cf3e97a40759.jpeg

The Shanghai Institute of Materia Medica (SIMM) under the Chinese Academy of Sciences, which jointly developed the drug with Ocean University of China and Green Valley Pharmaceutical Co Ltd, after research efforts of 22 years, said that so far, there are five medicines with limited efficacy treating the disease since it was discovered a century ago.

经过22年的研究,中国科学院上海药物研究所(SIMM)与中国海洋大学和绿谷药业有限公司共同研发了这种药物,该研究所表示,自100年前发现这种疾病以来,迄今仅有五种疗效有限的药物。

Alzheimer's disease, an irreversible, progressive brain disorder that slowly destroys memory, thinking ability, and the capability to carry out simple tasks, affects about 48 million people worldwide, and the number is expected to increase with the aging population. China has roughly 10 million people suffering from the disease, ranking first in the world.

阿尔茨海默症是一种不可逆的、渐进性的大脑疾病,它会缓慢地破坏人的记忆、思维能力和完成简单任务的能力。全球约有4800万人患有该疾病,预计随着人口老龄化,这一数字还会增加。中国约有1000万人患有该病,居世界首位。

In July last year, phase III clinical trials of the drug involving 818 patients were completed and "proven to continuously and effectively improve cognition among mild-to-moderate Alzheimer's disease sufferers over a period of nine months," said Geng Meiyu, lead researcher of the drug and a researcher with SIMM.

去年七月,该药物的三期临床试验已经完成,涉及818名患者。该药物的首席研究员、SIMM 的研究员耿美玉表示,“在为期36周的临床实验中,该药物被证明可以持续有效地改善轻度至中度阿尔茨海默症患者的认知能力。”

"Researches so far haven't found addiction and serious toxicity with the therapy," she said.

她说:“到目前为止,研究人员还没有发现药物成瘾和严重毒性。”

0 条评论
评论不能为空